This bill expands Medicare coverage to include in-home administration of intravenous immune globulin, or IVIG, a treatment that delivers antibodies through an IV line. Currently, Medicare covers IVIG for patients with primary immune deficiency diseases, but starting January 1, 2026, the bill extends coverage to also include patients with chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy, which are nerve disorders that weaken muscles. The legislation allows Medicare payment rates to vary based on which condition is being treated, with the specific payment differences to be determined by the Secretary of Health and Human Services through the standard rulemaking process. This change primarily benefits patients with these two neurological conditions who would otherwise have to travel to medical facilities for treatment, allowing them to receive therapy at home instead. The bill does not specify a funding amount but directs the government to establish appropriate payment rates for these new coverage categories by 2026.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.